Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The drug bebtelovimab isn't expected to neutralize now-common Omicron subvariants BQ. 1 and BQ. 1.1.

FDA Pulls Lilly's Covid Antibody Drug

Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease

AbbVie

Edwards Lifesciences

Intuitive Surgical

Johnson & Johnson

Merck

Walgreens

Amid rising concerns about the state of the global economy, rising inflation, central bank interest rate hikes and increased Covid-19 restrictions in China, marked indexes were mixed on Wednesday morning.

Gurus Prescribed These Health Care Stocks in the 3rd Quarter

Eli Lilly and Company (NYSE:LLY ) 5th Annual Evercore ISI HealthCONx Conference 2022 Conference Call November 30, 2022 12:10 PM ET Company Participants Jacob Van Naarden - Executive Vice President and Chief Executive Officer, Loxo@Lilly David Hyman - Chief Medical Officer, Loxo@Lilly Joe Fletcher - SVP, IR Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Excellent. Thank you, guys for joining us.

Eli Lilly and Company (LLY) Management Presents at 5th Annual Evercore ISI HealthCONx Conference 2022 Conference Call Transcript

Eli Lilly and Co's COVID-19 drug bebtelovimab is not currently authorized for emergency use in the United States, the Food and Drug Administration said, citing it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.

FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab

Akouos

INDIANAPOLIS and BOSTON , Nov. 30, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern time, on Nov. 29, 2022 and was not extended (such date and time, the "Expiration Time").

Lilly and Akouos Announce Expiration of Akouos Tender Offer

Apple

Broadcom

Check out these three S&P 500 stocks ahead of December 2022.

3 S&P 500 Stocks For Your December 2022 Watchlist

INDIANAPOLIS , Nov. 29, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial guidance.

Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement

Amgen

Bristol-Myers

Pfizer

Among the 19 companies that are expected to announce annual dividend increases in December are drugmakers Eli Lilly, Pfizer, Bristol Myers Squibb, and Amgen. Investors are also waiting for Merck's increase. We'll see several nice increases in December from other companies as well: Nucor, Mastercard, and Broadcom are all expected to announce 10%+ boosts.

4 Pharmaceutical Companies Among 19 To Announce Annual Dividend Increases In December

In the market meltdown of 2022, this pharmaceutical stock bucked the trend and rose significantly.

Up 32% in 2022, Is Eli Lilly Stock Still a Buy?

Eli Lilly and Company is fairly new to the dividend growth club. The company is finally growing robustly again.

Eli Lilly: Don't Take This Medicine

INDIANAPOLIS , Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022, in San Antonio, Texas, and virtually. These presentations include new results from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]), and LOXO-783 (an investigational mutant-selective allosteric PI3Kα H1047R inhibitor).

Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium

Furor over platform's verified profiles may have done some good, but challenges still plague the site after a mass worker exodus

‘More work to do': Eli Lilly admits insulin pricing could be lower amid Twitter chaos

Markets typically applaud the 'certainty' that comes with a split Congress.

How Markets Have Fared Under a Divided Congress

Investors shouldn't be overly concerned with the stock's earnings multiple -- a premium is justifiable for this top business.

3 Reasons Eli Lilly Is an Unstoppable Stock

Shopify

One of them is also crushing the bear market.

2 Stocks That Could Outperform the Next Bull Market

Lilly (LLY) expects to launch five new medicines by 2023-end, including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.

Eli Lilly (LLY) Stock Up 26.7% YTD: What's in Store for 2023?

UnitedHealth Group

Healthcare has long been a wise investment, as the industry consistently grows yearly. Some analysts believe that trend will continue.

Four Healthcare Stocks To Watch This Week

Forget the Twitter tumult. Lilly is a verified winner.

Is Eli Lilly Stock a Buy After Last Week's Twitter Prank?

Biogen

Biogen's BIIB, +4.96% stock is rising again as investors double down on the company's promising yet still experimental treatment for Alzheimer's disease.

One Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatments

Eli Lilly reportedly is pulling advertising from Twitter after a fake account promised free insulin in a fiasco that depressed LLY stock. The post Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads appeared first on Investor's Business Daily.

Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads

Eli Lilly and Co (NYSE:LLY) stock was moving higher as Roche revealed that an experimental rival treatment for Alzheimer's failed in a Phase III clinical trial. Roche earlier today announced that its drug candidate gantenerumab failed to slow dementia progression in a twin drug trial (Graduate 1 and 2).

Eli Lilly stock starts on front foot after rival Alzheimer trial fails

Prothena

Roche Holding AG

Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled. The post Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others appeared first on Investor's Business Daily.

Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others

Somehow, someone made it through Twitter's system to block accounts people use to impersonate other people and companies.

Twitter Shaves $15 Billon Off Eli Lilly's Market Cap

A scandal at Twitter is pushing healthcare stocks down today. Since Elon Musk took over the platform, much controversy has risen regarding its verification system.

News for Eli Lilly Stock (LLY)